Journal Article
. 2019 Jun; 381(4):307-316.
doi: 10.1056/NEJMoa1903765.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock-Ah Im 1 Yen-Shen Lu 1 Aditya Bardia 1 Nadia Harbeck 1 Marco Colleoni 1 Fabio Franke 1 Louis Chow 1 Joohyuk Sohn 1 Keun-Seok Lee 1 Saul Campos-Gomez 1 Rafael Villanueva-Vazquez 1 Kyung-Hae Jung 1 Arunava Chakravartty 1 Gareth Hughes 1 Ioannis Gounaris 1 Karen Rodriguez-Lorenc 1 Tetiana Taran 1 Sara Hurvitz 1 Debu Tripathy 1 
Affiliations
  • PMID: 31166679
  •     157 citations

Abstract

Background: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival.

Methods: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods.

Results: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87).

Conclusions: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments.
Daniele Presti, Erica Quaquarini.
Cancers (Basel), 2019 Aug 28; 11(9). PMID: 31450618    Free PMC article.
Review.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, +16 authors, Antonio Llombart-Cussac.
JAMA Oncol, 2019 Sep 30; 6(1). PMID: 31563959    Free PMC article.
Highly Cited.
Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.
Maira Huerta-Reyes, Guadalupe Maya-Núñez, +4 authors, Arturo Aguilar-Rojas.
Front Oncol, 2019 Oct 22; 9. PMID: 31632902    Free PMC article.
Review.
Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
Florian Schütz, Peter A Fasching, +16 authors, Volkmar Müller.
Geburtshilfe Frauenheilkd, 2019 Oct 28; 79(10). PMID: 31656318    Free PMC article.
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
Manfred Welslau, Andreas D Hartkopf, +17 authors, Tanja N Fehm.
Geburtshilfe Frauenheilkd, 2019 Oct 28; 79(10). PMID: 31656319    Free PMC article.
Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer.
Long V Nguyen, Karlee Searle, Katarzyna J Jerzak.
Oncotarget, 2019 Nov 07; 10(59). PMID: 31695840    Free PMC article.
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Emanuel Raschi, Fabrizio De Ponti.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708776    Free PMC article.
Review.
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion.
Ahmad Awada, Joseph Gligorov, +3 authors, Christoph Zielinski.
ESMO Open, 2019 Dec 05; 4(6). PMID: 31798979    Free PMC article.
Review.
Cancer biomarkers for targeted therapy.
Delong Liu.
Biomark Res, 2019 Dec 07; 7. PMID: 31807308    Free PMC article.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Valentina Rossi, Paola Berchialla, +11 authors, Alessandra Fabi.
Cancers (Basel), 2019 Nov 14; 11(11). PMID: 31717791    Free PMC article.
Efficacy of PI3K inhibitors in advanced breast cancer.
B Verret, J Cortes, +2 authors, M Arnedos.
Ann Oncol, 2019 Dec 21; 30(Suppl_10). PMID: 31859349    Free PMC article.
Review.
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Andreas D Hartkopf, Volkmar Müller, +16 authors, Diana Lüftner.
Geburtshilfe Frauenheilkd, 2019 Dec 27; 79(12). PMID: 31875860    Free PMC article.
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Vassilis Aggelis, Stephen R D Johnston.
Drugs, 2019 Oct 21; 79(17). PMID: 31630379
Review.
Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
Xueni Liu, Jianhui Huang, +3 authors, Jian Lou.
Med Sci Monit, 2019 Nov 25; 25. PMID: 31760402    Free PMC article.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Robert H Jones, Angela Casbard, +13 authors, Sacha J Howell.
Lancet Oncol, 2020 Feb 09; 21(3). PMID: 32035020    Free PMC article.
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
Christoph Thomssen, Diana Lüftner, +21 authors, Katja Ziegler-Löhr.
Breast Care (Basel), 2020 Apr 02; 15(1). PMID: 32231503    Free PMC article.
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Lei Ding, Jiaqi Cao, +6 authors, Qinghua Cui.
Int J Mol Sci, 2020 Mar 19; 21(6). PMID: 32183020    Free PMC article.
Review.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, +16 authors, Michael P Lux.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322108    Free PMC article.
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
Addie Hill, Eutiquio Gutierrez, +3 authors, Mina S Sedrak.
Drugs Aging, 2020 Apr 01; 37(5). PMID: 32227289    Free PMC article.
Review.
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
Marco De Dominici, Patrizia Porazzi, +13 authors, Bruno Calabretta.
Blood, 2020 Feb 11; 135(18). PMID: 32040545    Free PMC article.
Major clinical research advances in gynecologic cancer in 2019.
Miseon Kim, Dong Hoon Suh, +6 authors, Jae Weon Kim.
J Gynecol Oncol, 2020 Apr 23; 31(3). PMID: 32319232    Free PMC article.
Review.
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
Bishal Gyawali, Spencer P Hey, Aaron S Kesselheim.
EClinicalMedicine, 2020 May 10; 21. PMID: 32382717    Free PMC article.
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.
Anja Welt, Simon Bogner, +14 authors, Mitra Tewes.
J Cancer Res Clin Oncol, 2020 Mar 20; 146(6). PMID: 32189107    Free PMC article.
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
Yanmei Wu, Yu Zhang, Hao Pi, Yuan Sheng.
Cancer Manag Res, 2020 Jun 12; 12. PMID: 32523378    Free PMC article.
Review.
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
Ami N Shah, Otto Metzger, +3 authors, Massimo Cristofanilli.
Oncologist, 2020 Mar 17; 25(6). PMID: 32176406    Free PMC article.
Review.
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Jiani Zheng, Jingxun Wu, +3 authors, Feng Ye.
PLoS One, 2020 Jun 05; 15(6). PMID: 32497134    Free PMC article.
Systematic Review.
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Le-Sang Shen, Xiao-Yan Jin, +2 authors, Jian Huang.
Chin Med J (Engl), 2020 Apr 09; 133(9). PMID: 32265426    Free PMC article.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Giacomo Barchiesi, Marco Mazzotta, +14 authors, Patrizia Vici.
Int J Mol Sci, 2020 May 21; 21(10). PMID: 32429381    Free PMC article.
Review.
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.
Erik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi.
Am Soc Clin Oncol Educ Book, 2020 May 19; 40. PMID: 32421454    Free PMC article.
Review.
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results.
Michael Untch, Rachel Würstlein, +20 authors, Nadia Harbeck.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565549    Free PMC article.
Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model.
Vince Kornél Grolmusz, Jinfeng Chen, +5 authors, Andrea H Bild.
Cancer Cell Int, 2020 Jun 23; 20. PMID: 32565737    Free PMC article.
Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Ning Xie, Tao Qin, +3 authors, Huangming Hong.
Cancer Manag Res, 2020 Jun 26; 12. PMID: 32581595    Free PMC article.
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
I Alvarez-Lopez, S Bezares, +6 authors, A Santaballa Bertrán.
Clin Transl Oncol, 2020 Feb 14; 22(8). PMID: 32052382    Free PMC article.
Systematic Review.
Breast Cancer Survivorship, Quality of Life, and Late Toxicities.
Simone Nardin, Edoardo Mora, +6 authors, Alessandra Gennari.
Front Oncol, 2020 Jul 03; 10. PMID: 32612947    Free PMC article.
Review.
Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors.
N J Lipton, J Jesin, +4 authors, K J Jerzak.
Curr Oncol, 2020 Jul 17; 27(3). PMID: 32669921    Free PMC article.
Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.
Jocelyn Luveta, Ruth M Parks, +2 authors, Simon J Johnston.
Oncol Ther, 2020 Jul 24; 8(1). PMID: 32700069    Free PMC article.
Review.
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.
Anne Fassl, Christopher Brain, +26 authors, Piotr Sicinski.
Sci Adv, 2020 Jul 25; 6(25). PMID: 32704543    Free PMC article.
Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.
Mireia Margelí Vila, Sonia Del Barco Berron, +2 authors, Rafael Villanueva Vázquez.
Breast, 2020 Jul 06; 53. PMID: 32623094    Free PMC article.
Review.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Richard S Finn, Katalin Boer, +13 authors, Johannes Ettl.
Breast Cancer Res Treat, 2020 Jul 20; 183(2). PMID: 32683565    Free PMC article.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Lillian M Smyth, Kenji Tamura, +25 authors, David M Hyman.
Clin Cancer Res, 2020 Apr 22; 26(15). PMID: 32312891    Free PMC article.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
Masanori Oshi, Hideo Takahashi, +6 authors, Kazuaki Takabe.
Cells, 2020 Jul 12; 9(7). PMID: 32650578    Free PMC article.
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Nadia Harbeck, Fabio Franke, +10 authors, Aditya Bardia.
Ther Adv Med Oncol, 2020 Aug 13; 12. PMID: 32782490    Free PMC article.
Novel targeted therapies for metastatic breast cancer.
Khalid Jazieh, Ruth Bell, Nayan Agarwal, Jame Abraham.
Ann Transl Med, 2020 Aug 15; 8(14). PMID: 32793751    Free PMC article.
Review.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Neil A O'Brien, Martina S J McDermott, +13 authors, Dennis J Slamon.
Breast Cancer Res, 2020 Aug 17; 22(1). PMID: 32795346    Free PMC article.
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Elena Fountzilas, Georgia-Angeliki Koliou, +27 authors, Georgios Koumakis.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817060    Free PMC article.
In the literature: August 2020.
Valentina Gambardella, Juan-Miguel Cejalvo, Noelia Tarazona, Andrés Cervantes.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817070    Free PMC article.
Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths.
Tomás Reinert, Rodrigo Pellegrini, Carlos Henrique Barrios.
Ecancermedicalscience, 2020 Aug 31; 14. PMID: 32863875    Free PMC article.
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Mariana Brandão, Christian Maurer, +7 authors, Matteo Lambertini.
ESMO Open, 2020 Aug 28; 5(4). PMID: 32847835    Free PMC article.
Systematic Review.
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Yoon-Sim Yap, Joanne Chiu, +12 authors, Norikazu Masuda.
Cancer Sci, 2020 Jul 04; 111(9). PMID: 32619077    Free PMC article.
Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity.
Noman Ahmed Jang Khan, Mohamed Alsharedi.
Cureus, 2020 Sep 12; 12(9). PMID: 32913695    Free PMC article.
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Sudpreeda Chainitikun, James P Long, +4 authors, Naoto T Ueno.
Breast Cancer Res Treat, 2020 Jul 29; 183(3). PMID: 32720114    Free PMC article.
Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58.
Xusu Wang, Guangquan Liu, +8 authors, Juan Xu.
Ann Transl Med, 2020 Sep 22; 8(15). PMID: 32953725    Free PMC article.
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra, Giuseppe Curigliano.
NPJ Breast Cancer, 2019 Sep 05; 5. PMID: 31482107    Free PMC article.
Review.
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Rossana Roncato, Jacopo Angelini, +6 authors, Giuseppe Toffoli.
Int J Mol Sci, 2020 Sep 05; 21(17). PMID: 32883002    Free PMC article.
Review.
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Michela Piezzo, Paolo Chiodini, +12 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Sep 10; 21(17). PMID: 32899139    Free PMC article.
Systematic Review.
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Luc Cabel, Dan Rosenblum, +11 authors, François-Clément Bidard.
Breast Cancer Res, 2020 Sep 16; 22(1). PMID: 32928264    Free PMC article.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Andreas Schneeweiss, Johannes Ettl, +31 authors, Sara Y Brucker.
Breast, 2020 Sep 22; 54. PMID: 32956934    Free PMC article.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment.
Andreas D Hartkopf, Eva-Maria Grischke, Sara Y Brucker.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982644    Free PMC article.
Review.
Early treatment-related neutropenia predicts response to palbociclib.
Nicholas P McAndrew, Mark A Dickson, +10 authors, Angela DeMichele.
Br J Cancer, 2020 Jul 10; 123(6). PMID: 32641862    Free PMC article.
CDK4/6 Dependence of Cyclin D1-Driven Parathyroid Neoplasia in Transgenic Mice.
Jessica Costa-Guda, Kristin Corrado, +8 authors, Andrew Arnold.
Endocrinology, 2020 Sep 03; 161(10). PMID: 32877917    Free PMC article.
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Michela Piezzo, Stefania Cocco, +8 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Sep 10; 21(18). PMID: 32899866    Free PMC article.
Review.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Peter A Fasching, J Thaddeus Beck, +13 authors, Arnd Nusch.
Breast, 2020 Oct 17; 54. PMID: 33065342    Free PMC article.
Integrating Old and New Paradigms of G1/S Control.
Seth M Rubin, Julien Sage, Jan M Skotheim.
Mol Cell, 2020 Sep 19; 80(2). PMID: 32946743    Free PMC article.
Review.
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
Debora de Melo Gagliato, Antonio C Buzaid, +2 authors, Javier Cortes.
Cancers (Basel), 2020 Sep 05; 12(9). PMID: 32882980    Free PMC article.
Review.
FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells.
Shuya Yano, Hiroshi Tazawa, +2 authors, Robert M Hoffman.
Cancers (Basel), 2020 Sep 23; 12(9). PMID: 32957652    Free PMC article.
Review.
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
Jesús Fuentes-Antrás, Alicia de Luna, +3 authors, Fernando Moreno.
Breast, 2020 Oct 24; 54. PMID: 33096323    Free PMC article.
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib.
Misty Shields, Qianxing Mo, +2 authors, Ricardo L B Costa.
Oncotarget, 2020 Nov 05; 11(42). PMID: 33144920    Free PMC article.
Review.
Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis.
Siqi Liu, Xin Sun, Xiaohui Xu, Fangcai Lin.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154823    Free PMC article.
Review.
Targeting Autophagy in Breast Cancer.
Stefania Cocco, Alessandra Leone, +8 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Oct 28; 21(21). PMID: 33105796    Free PMC article.
Review.
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
François-Clément Bidard, William Jacot, +22 authors, Jean-Yves Pierga.
JAMA Oncol, 2020 Nov 06; 7(1). PMID: 33151266    Free PMC article.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, +16 authors, Wolfgang Janni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173239    Free PMC article.
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Martine C Maculaitis, Xianchen Liu, +4 authors, Melissa Crastnopol.
Patient Prefer Adherence, 2020 Nov 13; 14. PMID: 33177814    Free PMC article.
Characterization of the Synergistic Inhibition of IK(erg) and IK(DR) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor.
Pin-Yen Liu, Wei-Ting Chang, Sheng-Nan Wu.
Int J Mol Sci, 2020 Nov 04; 21(21). PMID: 33138174    Free PMC article.
Opportunities for Antigen Discovery in Metastatic Breast Cancer.
Ashwani K Sood, Michael Nemeth, +2 authors, Shipra Gandhi.
Front Immunol, 2020 Nov 17; 11. PMID: 33193348    Free PMC article.
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.
Mingxi Lin, Yang Chen, +2 authors, Jian Zhang.
J Cancer, 2020 Nov 17; 11(24). PMID: 33193875    Free PMC article.
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2-Rb wild-type and knock-down in breast cancer cell lines.
Oliviero Marinelli, Emanuela Romagnoli, +6 authors, Giorgio Santoni.
BMC Cancer, 2020 Nov 21; 20(1). PMID: 33213401    Free PMC article.
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Francesco Schettini, Fabiola Giudici, +17 authors, Daniele Generali.
J Natl Cancer Inst, 2020 May 15; 112(11). PMID: 32407488    Free PMC article.
Systematic Review.
Ribociclib in Breast Cancer Brain Metastases: A Case Report.
Isabel Radke, Marie-Kristin von Wahlde, Christoph Schülke, Joke Tio.
Breast Care (Basel), 2020 Nov 24; 15(5). PMID: 33224000    Free PMC article.
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10).
Soohyeon Lee, Seock-Ah Im, +12 authors, Yeon Hee Park.
Cancers (Basel), 2020 Nov 11; 12(11). PMID: 33167305    Free PMC article.
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis.
Jacques Raphael, Cory Lefebvre, +4 authors, Phillip S Blanchette.
Target Oncol, 2020 Nov 06; 15(6). PMID: 33151471
Review.
Trends and patterns in the use of opioids among metastatic breast cancer patients.
Chan Shen, J Douglas Thornton, +5 authors, Douglas Leslie.
Sci Rep, 2020 Dec 12; 10(1). PMID: 33303832    Free PMC article.
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.
Claudia De Angelis, Michail Ignatiadis, Martine Piccart-Gebhart.
Ann Transl Med, 2020 Dec 15; 8(21). PMID: 33313083    Free PMC article.
CDK 4/6 inhibitors combined with radiotherapy: A review of literature.
Claire Bosacki, Wafa Bouleftour, +7 authors, Nicolas Magné.
Clin Transl Radiat Oncol, 2020 Dec 16; 26. PMID: 33319074    Free PMC article.
Review.
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
Terry L Ng, Megan M Tu, +12 authors, Mark J Clemons.
Support Care Cancer, 2020 Jun 15; 29(2). PMID: 32535678
Systematic Review.
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
C Louwrens Braal, Elisabeth M Jongbloed, +3 authors, Agnes Jager.
Drugs, 2020 Dec 29; 81(3). PMID: 33369721    Free PMC article.
Review.
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
Armando Orlandi, Elena Iattoni, +21 authors, Giampaolo Tortora.
J Pers Med, 2020 Dec 24; 10(4). PMID: 33353132    Free PMC article.
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Jiangping Yang, Jiaqi Han, +3 authors, Xi Yan.
Cancer Manag Res, 2020 Dec 29; 12. PMID: 33364838    Free PMC article.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Sanne Løkkegaard, Daniel Elias, +17 authors, Henrik J Ditzel.
NPJ Breast Cancer, 2021 Jan 06; 7(1). PMID: 33398005    Free PMC article.
The immunomodulatory effects of endocrine therapy in breast cancer.
Huanhuan Huang, Jun Zhou, +4 authors, Chao Ni.
J Exp Clin Cancer Res, 2021 Jan 09; 40(1). PMID: 33413549    Free PMC article.
Review.
Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer.
Maithreyi Sarma, Yara Abdou, Ajay Dhakal, Shipra Gandhi.
Breast Cancer (Auckl), 2021 Jan 07; 14. PMID: 33402826    Free PMC article.
Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.
Lakyn Husinka, Pamela H Koerner, Rick T Miller, William Trombatt.
J Drug Assess, 2021 Jan 09; 10(1). PMID: 33414982    Free PMC article.
The prognosis of early-stage breast cancer in extremely young female patients.
Wei-Pang Chung, Kuo-Ting Lee, +4 authors, Hui-Ping Hsu.
Medicine (Baltimore), 2021 Jan 13; 100(1). PMID: 33429771    Free PMC article.
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.
Andreas Schneeweiss, Ingo Bauerfeind, +5 authors, Volkmar Müller.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447235    Free PMC article.
Review.
miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by Inhibiting CXCL11.
Jie Zhang, Dawei Hu.
Cancer Manag Res, 2021 Jan 21; 13. PMID: 33469358    Free PMC article.
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Shumei Kato, Ryosuke Okamura, +5 authors, Razelle Kurzrock.
JCI Insight, 2021 Jan 12; 6(1). PMID: 33427211    Free PMC article.
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Michela Roberto, Antonio Astone, +19 authors, Paolo Marchetti.
Cancers (Basel), 2021 Jan 23; 13(2). PMID: 33477469    Free PMC article.
Review.
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Gayathri Nagaraj, Cynthia X Ma.
Adv Ther, 2020 Nov 16; 38(1). PMID: 33190190    Free PMC article.
Review.
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer.
Aditi S Khatpe, Adedeji K Adebayo, +2 authors, Harikrishna Nakshatri.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33498407    Free PMC article.
Review.
Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence.
Theresa Wicklin Gillespie.
J Adv Pract Oncol, 2021 Feb 06; 11(1). PMID: 33542852    Free PMC article.
Review.
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
Kristina F Byers.
J Adv Pract Oncol, 2021 Feb 09; 12(1). PMID: 33552665    Free PMC article.
Regulation of aromatase in cancer.
Deborah Molehin, Fahmida Rasha, Rakhshanda Layeequr Rahman, Kevin Pruitt.
Mol Cell Biochem, 2021 Feb 19; 476(6). PMID: 33599895
Review.
Hormone Receptor-Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices.
Lee Schwartzberg, Heather Greene.
J Adv Pract Oncol, 2021 Feb 19; 11(3). PMID: 33598325    Free PMC article.
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Marion Bertho, Julien Fraisse, +21 authors, Jean-Sébastien Frénel.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613700    Free PMC article.
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.
Daniel Stellato, Marroon Thabane, Caitlin Eichten, Thomas E Delea.
Curr Oncol, 2021 Jan 21; 28(1). PMID: 33466914    Free PMC article.
Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.
Aldo Prawira, Thi Bich Uyen Le, Thanh Chung Vu, Hung Huynh.
Liver Int, 2020 Nov 13; 41(3). PMID: 33179425    Free PMC article.
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Francesco Schettini, Mario Giuliano, +18 authors, Daniele Generali.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33810205    Free PMC article.
Review.
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Kristoffer B Kristensen, Ida Marie Nedergaard Thomsen, +2 authors, Anders Bonde Jensen.
Breast Cancer Res Treat, 2021 Apr 11; 188(3). PMID: 33837869
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Maria Alice Franzoi, Rita Saúde-Conde, +3 authors, Evandro de Azambuja.
Breast, 2021 Apr 03; 57. PMID: 33799232    Free PMC article.
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Debora Basile, Lorenzo Gerratana, +15 authors, Fabio Puglisi.
Breast, 2021 Apr 04; 57. PMID: 33812267    Free PMC article.
Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer.
Hikmat Abdel-Razeq, Mahmoud Abunasser, +2 authors, Jakub Khzouz.
Cureus, 2021 Apr 29; 13(3). PMID: 33907637    Free PMC article.
Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
Jieun Lee, Hyung Soon Park, +8 authors, Jae Ho Byun.
Cancer Res Treat, 2020 Nov 04; 53(2). PMID: 33138346    Free PMC article.
Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies.
Carlos Barrios, Ruffo Freitas-Junior, +3 authors, Maira Caleffi.
JCO Glob Oncol, 2021 Apr 07; 7. PMID: 33822641    Free PMC article.
Review.
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
Emanuel Raschi, Michele Fusaroli, +2 authors, Fabrizio De Ponti.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33917020    Free PMC article.
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Malinda T West, Claire E Smith, +7 authors, Joseph J Shatzel.
Eur J Haematol, 2021 Feb 03; 106(5). PMID: 33527479    Free PMC article.
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Jinming Li, Xingfa Huo, +5 authors, Jiuda Zhao.
JAMA Netw Open, 2020 Oct 14; 3(10). PMID: 33048129    Free PMC article.
Systematic Review.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Lillian M Smyth, Gerald Batist, +24 authors, Sarat Chandarlapaty.
NPJ Breast Cancer, 2021 Apr 18; 7(1). PMID: 33863913    Free PMC article.
Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer: a Brazilian private payer perspective.
Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne, Stephen Stefani.
Ther Adv Med Oncol, 2021 May 06; 13. PMID: 33948121    Free PMC article.
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
Lydia Loke, Soo-Chin Lee, +2 authors, Mohamed Ismail Abdul Aziz.
Cancer Rep (Hoboken), 2020 Oct 22; 4(1). PMID: 33085843    Free PMC article.
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.
Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, François Bertucci.
NPJ Breast Cancer, 2021 May 07; 7(1). PMID: 33953185    Free PMC article.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
B Gyawali, E G E de Vries, +20 authors, N I Cherny.
ESMO Open, 2021 Apr 23; 6(3). PMID: 33887690    Free PMC article.
Review.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
T Grinda, A Antoine, +24 authors, S Delaloge.
ESMO Open, 2021 Apr 26; 6(3). PMID: 33895695    Free PMC article.
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
Jason Schick, Raquel P Ritchie, Carolina Restini.
Breast Cancer (Auckl), 2021 May 18; 15. PMID: 33994789    Free PMC article.
Review.
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
Anna Hester, Franziska Henze, +2 authors, Rachel Wuerstlein.
Breast Care (Basel), 2021 May 21; 16(2). PMID: 34012367    Free PMC article.
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
Athanasios Mavratzas, Frederik Marmé.
Breast Care (Basel), 2021 May 21; 16(2). PMID: 34012366    Free PMC article.
Review.
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.
Eunae Jeong, Changjun Wang, Leslie Wilson, Lixian Zhong.
Front Oncol, 2021 May 25; 11. PMID: 34026637    Free PMC article.
Targeting pan-essential genes in cancer: Challenges and opportunities.
Liang Chang, Paloma Ruiz, Takahiro Ito, William R Sellers.
Cancer Cell, 2021 Jan 16; 39(4). PMID: 33450197    Free PMC article.
Review.
Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers.
Nina Ditsch, Elmar Stickeler, +24 authors, Bahriye Aktas.
Geburtshilfe Frauenheilkd, 2021 May 27; 81(5). PMID: 34035548    Free PMC article.
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Mario Hlevnjak, Markus Schulze, +28 authors, Andreas Schneeweiss.
JCO Precis Oncol, 2021 May 27; 5. PMID: 34036222    Free PMC article.
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Samitha Andrahennadi, Amer Sami, +2 authors, Shahid Ahmed.
Curr Oncol, 2021 Jun 03; 28(3). PMID: 34064867    Free PMC article.
Review.
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer.
Toshiaki Iwase, Tushaar Vishal Shrimanker, +5 authors, Naoto T Ueno.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071219    Free PMC article.
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer.
Ilenia Migliaccio, Angela Leo, +6 authors, Luca Malorni.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34072070    Free PMC article.
Review.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
Aleix Prat, Anwesha Chaudhury, +9 authors, Fei Su.
J Clin Oncol, 2021 Mar 27; 39(13). PMID: 33769862    Free PMC article.
PARP14 regulates cyclin D1 expression to promote cell-cycle progression.
Michael J O'Connor, Tanay Thakar, Claudia M Nicolae, George-Lucian Moldovan.
Oncogene, 2021 Jun 24; 40(30). PMID: 34158578    Free PMC article.
ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis.
Valery Adorno-Cruz, Andrew D Hoffmann, +5 authors, Huiping Liu.
Genes Dis, 2020 Feb 01; 8(4). PMID: 34179312    Free PMC article.
Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives.
Alessandra Dall'Acqua, Michele Bartoletti, +4 authors, Gustavo Baldassarre.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34204543    Free PMC article.
Review.
Oligometastatic Breast Cancer: How to Manage It?
Vittoria Barberi, Antonella Pietragalla, +6 authors, Alessandra Fabi.
J Pers Med, 2021 Jul 03; 11(6). PMID: 34207648    Free PMC article.
Review.
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
Stephen Johnston, Joyce O'Shaughnessy, +7 authors, Matthew P Goetz.
NPJ Breast Cancer, 2021 Jun 24; 7(1). PMID: 34158513    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.
Marc Thill, Michael Friedrich, +43 authors, Nina Ditsch.
Breast Care (Basel), 2021 Jul 13; 16(3). PMID: 34248463    Free PMC article.
Review.
Ribociclib-Induced Pneumonitis: A Case Report.
Ghada Algwaiz, Ahmed Ali Badran, Mahmoud A Elshenawy, Taher Al-Tweigeri.
Breast Care (Basel), 2021 Jul 13; 16(3). PMID: 34248473    Free PMC article.
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Amy S Clark, Igor Makhlin, Angela DeMichele.
Clin Cancer Res, 2020 Nov 05; 27(2). PMID: 33144339    Free PMC article.
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
Carla P Amaro, Atul Batra, Sasha Lupichuk.
Curr Oncol, 2021 Jul 03; 28(3). PMID: 34207443    Free PMC article.
Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer.
Alistair Ring, Nicolò Matteo Luca Battisti, +33 authors, Age Gap TMG.
Br J Cancer, 2021 May 12; 125(2). PMID: 33972747    Free PMC article.
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer.
Huayi Li, Lorenzo Prever, Emilio Hirsch, Federico Gulluni.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298731    Free PMC article.
Review.
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
Mridula A George, Sadaf Qureshi, +2 authors, Shridar Ganesan.
Front Oncol, 2021 Jul 31; 11. PMID: 34327137    Free PMC article.
Review.
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Jiyun Lee, Seock-Ah Im, +6 authors, Yeon Hee Park.
Cancer Res Treat, 2020 Dec 18; 53(3). PMID: 33332933    Free PMC article.
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials.
E Panagiotou, G Gomatou, +2 authors, E Kotteas.
Clin Transl Oncol, 2021 Aug 08;. PMID: 34363593
Review.
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
Michela Palleschi, Gianluca Tedaldi, +3 authors, Ugo De Giorgi.
Int J Mol Sci, 2021 Aug 08; 22(15). PMID: 34360649    Free PMC article.
Review.
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Shaheenah Dawood, Maria Konstantionva, +6 authors, Sergio Simon.
BMC Proc, 2021 Aug 11; 15(Suppl 10). PMID: 34372853    Free PMC article.
Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
A Davie, G Cuyun Carter, +6 authors, X Pivot.
ESMO Open, 2021 Aug 10; 6(4). PMID: 34371379    Free PMC article.
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Fangfang Duan, Chenge Song, +10 authors, Wen Xia.
Drug Des Devel Ther, 2021 Aug 20; 15. PMID: 34408400    Free PMC article.
Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.
Mikko Moisander, Annukka Salminen, +7 authors, Otso Arponen.
Acta Radiol Open, 2021 Aug 24; 10(8). PMID: 34422318    Free PMC article.
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Kenichi Inoue, Norikazu Masuda, +13 authors, Masakazu Toi.
Breast Cancer, 2021 Apr 03; 28(5). PMID: 33797023    Free PMC article.
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Carla L Alves, Sidse Ehmsen, +11 authors, Henrik J Ditzel.
Nat Commun, 2021 Aug 27; 12(1). PMID: 34433817
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Patrick Neven, Hope S Rugo, +8 authors, George W Sledge.
Breast Cancer Res, 2021 Aug 25; 23(1). PMID: 34425869    Free PMC article.